Sanofi (MEX:SNY) Change In Receivables : MXN-3,093 Mil (TTM As of Jun. 2024)

View and export this data going back to 2009. Start your Free Trial

What is Sanofi Change In Receivables?

Sanofi's change in receivables for the quarter that ended in Jun. 2024 was MXN276 Mil. It means Sanofi's Accounts Receivable declined by MXN276 Mil from Dec. 2023 to Jun. 2024 .

Sanofi's change in receivables for the fiscal year that ended in Dec. 2023 was MXN-7,349 Mil. It means Sanofi's Accounts Receivable increased by MXN7,349 Mil from Dec. 2022 to Dec. 2023 .

Sanofi's Accounts Receivable for the quarter that ended in Jun. 2024 was MXN167,819 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed. Sanofi's Days Sales Outstanding for the six months ended in Jun. 2024 was 69.03.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. Sanofi's liquidation value for the six months ended in Jun. 2024 was MXN-754,812 Mil.

Sanofi Change In Receivables Historical Data

The historical data trend for Sanofi's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sanofi Change In Receivables Chart

Sanofi Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Change In Receivables

Get a 7-Day Free Trial

-9,681.47

-3,242.74

4,288.24

-16,047.03

-7,348.72

Sanofi Semi-Annual Data
	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24
Change In Receivables	Get a 7-Day Free Trial															382.80	-16,418.77	-3,993.43	-3,368.94	276.08

Sanofi Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Jun. 2024 adds up the semi-annually data reported by the company within the most recent 12 months, which was MXN-3,093 Mil.

Sanofi (MEX:SNY) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Sanofi's Days Sales Outstanding for the quarter that ended in Jun. 2024 is calculated as:

	Days Sales Outstanding
=	Accounts Receivable	/	Revenue	*	Days in Period
=	167819.243	/	443665.96	*	91
=	69.03

2. In Ben Graham's calculation of liquidation value, Sanofi's accounts receivable are only considered to be worth 75% of book value:

Sanofi's liquidation value for the quarter that ended in Jun. 2024 is calculated as:

	Liquidation Value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	133999.031	-	1119281.384	+	0.75 * 167819.243	+	0.5 * 209212.027
=	-754,812

Sanofi Change In Receivables Related Terms

Thank you for viewing the detailed overview of Sanofi's Change In Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.

Sanofi Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Sanofi SA (MEX:SNY) » Definitions » Change In Receivables

Comparable Companies

Traded in Other Exchanges

SNYNF:USA SNY:USA 1SAN:Italy SANp:UK 0O59:UK SAN:France SNW:Germany SNW:Germany SNW:Germany SNW2:Germany SNW:Germany SNW:Bulgaria SANO:Austria

Address

46, avenue de la Great Army, Paris, FRA, 75017

Website

https://www.sanofi.com

Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, over-the-counter treatments and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 20% of total sales, but profits are shared with Regeneron. Just over 40% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.